骨桥蛋白作为胰腺癌和慢性胰腺炎的鉴别标志物。

Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.

作者信息

Rychlíková Jana, Vecka Marek, Jáchymová Marie, Macášek Jaroslav, Hrabák Petr, Zeman Miroslav, Vávrová Lucie, Řoupal Jan, Krechler Tomáš, Ák Aleš

机构信息

4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine Charles University in Prague, Prague, Czech Republic.

出版信息

Cancer Biomark. 2016 Jun 7;17(1):55-65. doi: 10.3233/CBM-160617.

DOI:10.3233/CBM-160617

PMID:27314293

Abstract

INTRODUCTION

We analyzed concentrations of osteopontin (OPN) in patients with pancreatic ductal adenocarcinoma (PDAC) in order to determine firstly whether it is useful to distinguish between PDAC patients and those with chronic non-hereditary pancreatitis (CP) and type 2 diabetes mellitus (T2DM), and secondly whether OPN concentrations depend on the PDAC stage.

METHODS

Groups consisting of 64 patients with PDAC, 71 with CP, 67 with T2DM and 48 healthy controls (CON) were enrolled in the study. Controls were compared with regard to levels of OPN, oxidative stress markers, conventional tumor markers and other biochemical parameters.

RESULTS

Levels of OPN were higher in patients with PDAC compared with CP patients (P< 0.001), T2DM (P< 0.001) and CON (P< 0.001). There were increased OPN levels in CP patients in comparison with T2DM (P< 0.001) and CON (P< 0.001). Patients with PDAC in stage IV had higher OPN levels than PDAC patients in stage III (P< 0.01). There was no difference in OPN levels of PDAC patients in stage III compared to patients in stage II.

CONCLUSION

Our pilot study demonstrates the usefulness of estimating OPN levels to differentiate between pancreatic cancer and chronic pancreatitis. Higher OPN levels over 102 ng/ml could be a potential diagnostic biomarker for pancreatic cancer.

摘要

引言

我们分析了胰腺导管腺癌（PDAC）患者骨桥蛋白（OPN）的浓度，目的一是确定其对于区分PDAC患者与慢性非遗传性胰腺炎（CP）和2型糖尿病（T2DM）患者是否有用，二是确定OPN浓度是否取决于PDAC分期。

方法

本研究纳入了由64例PDAC患者、71例CP患者、67例T2DM患者和48例健康对照者（CON）组成的几组对象。对对照组与其他组在OPN水平、氧化应激标志物、传统肿瘤标志物及其他生化参数方面进行比较。

结果

与CP患者（P<0.001）、T2DM患者（P<0.001）和CON（P<0.001）相比，PDAC患者的OPN水平更高。与T2DM患者（P<0.001）和CON（P<0.001）相比，CP患者的OPN水平升高。IV期PDAC患者的OPN水平高于III期PDAC患者（P<0.01）。III期PDAC患者与II期患者的OPN水平无差异。